Market Overview

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

Share:

Allogene Therapeutics, Inc., a clinical-stage biotechnology company
pioneering the development of allogeneic CAR T therapies for cancer,
today announced the appointment of Susie Jun, M.D., Ph.D., as Chief
Development Officer. In her new role at Allogene, she will focus on
creating an integrated translational research capability to accelerate
clinical development of Allogene's broad allogeneic CAR T cell portfolio.

"Susie is an exceptional physician/scientist and strategic thinker with
demonstrated expertise in innovative clinical development of novel
therapeutics in hematology and oncology," said David Chang, M.D., Ph.D.,
President, Chief Executive Officer and Co-Founder of Allogene. "As the
field of engineered cell therapy expands, it is critical to identify
ways to improve product characterization and predict treatment outcomes.
We welcome her to our management team and look forward to her
contributions as we continue to advance the development of our
potentially transformational allogeneic CAR T cell therapies."

Dr. Jun has more than 20 years of hematology and oncology clinical
research experience across academia and the biopharmaceutical industry.
Prior to joining Allogene, she served as Vice President, Head of
Development for Abbvie-Stemcentrx Development and also led the Companion
Diagnostics Center of Excellence at Abbvie. Dr. Jun has also served as
Senior Director, Hem/Onc Clinical Research, at Gilead, and as Executive
Medical Director, Hematology/Oncology, at Amgen where she led the
development of innovative oncology programs such as XGEVA®,
Nplate® and BLINCYTO®.

"Throughout my career, I have been dedicated to advancing medical
science and serving cancer patients by focusing on transformational
therapies that target unmet medical needs," said Dr. Jun. "Allogene,
with its pioneering science, has the potential to transform cancer
treatment. I look forward to working with the Allogene team to advance
the development of multiple allogeneic CAR T therapies to treat
hematological malignancies and solid tumors."

Dr. Jun received her M.D. from the University of Michigan Medical
School, and her Ph.D. from The Rockefeller University. She completed her
residency in internal medicine at Parkland Memorial Hospital,
UT-Southwestern in Dallas, and her fellowship in medical oncology and
hematology at Memorial Sloan Kettering Cancer Center in New York City.

Allogene is advancing its allogeneic CAR T cell portfolio acquired from
Pfizer, which includes rights to 16 preclinical CAR T cell therapy
targets licensed from Cellectis and Servier and U.S. rights to UCART19,
an allogeneic CAR T cell therapy candidate that is being developed for
the treatment of CD19-expressing hematological malignancies. In
partnership with Servier, UCART19 is in Phase 1 development for the
treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

About Allogene Therapeutics

Allogene Therapeutics is a clinical stage biotechnology company
pioneering the development of allogeneic chimeric antigen receptor
T-cell (CAR T) therapies for cancer. Led by a world-class management
team with significant experience in cell therapy, Allogene is developing
a pipeline of "off-the-shelf" CAR T cell therapy candidates with the
goal of delivering readily available cell therapy faster, more reliably
and at greater scale to more patients.

Allogeneic CAR T cell therapies are engineered from cells of healthy
donors which is intended to allow for creation of inventory for
"off-the-shelf" use in patients. This approach is designed to eliminate
the need to create personalized therapy from a patient's own cells,
simplify manufacturing, and reduce the time patients must wait for CAR T
cell treatment. The Allogene portfolio includes rights to 16
pre-clinical CAR T cell therapy targets and UCART19, an allogeneic CAR T
therapy candidate currently in Phase 1 development for the treatment of
relapsed/refractory acute lymphoblastic leukemia (ALL).

Through its notable partnerships, Allogene leverages pioneering
technology platforms, including TALEN® gene-editing
technology from Cellectis, to progress its portfolio of CAR T cell
therapies. Allogene, with headquarters in South San Francisco,
California, is a Two River portfolio company formed with one of the
largest Series A financings in biotechnology from an investment
consortium that includes TPG, Vida Ventures, BellCo Capital, the
University of California Office of the Chief Investment Officer, Gilead
and Pfizer. For more information, please visit www.allogene.com, and
follow @AllogeneTx on Twitter and LinkedIn.

XGEVA®, Nplate® and BLINCYTO® are
registered trademarks of Amgen Inc.

View Comments and Join the Discussion!